Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTXNASDAQ:ITRMNASDAQ:KRONNYSE:NHWK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$1.25-3.8%$1.28$0.85▼$4.40$40.22M0.2931,709 shs102 shsITRMIterum Therapeutics$1.01+2.6%$1.09$0.81▼$3.02$40.20M2.911.03 million shs41,138 shsKRONKronos Bio$0.67+0.2%$0.78$0.65▼$1.60$40.97M1.75312,006 shs5,447 shsNHWKNightHawk Biosciences$0.39$0.26▼$1.16$10.78M0.1997,242 shs173,100 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics-0.38%+1.57%-5.47%+48.85%-27.65%ITRMIterum Therapeutics-1.01%+5.25%-7.55%-29.75%-24.03%KRONKronos Bio+0.15%-2.40%-25.31%-31.48%-15.53%NHWKNightHawk Biosciences0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKTXAkari TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AITRMIterum Therapeutics1.9068 of 5 stars3.53.00.00.03.00.00.0KRONKronos Bio3.6964 of 5 stars3.25.00.00.03.03.31.3NHWKNightHawk BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari Therapeutics 0.00N/AN/AN/AITRMIterum Therapeutics 3.00Buy$9.00795.52% UpsideKRONKronos Bio 2.33Hold$1.63141.46% UpsideNHWKNightHawk Biosciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NHWK, AKTX, KRON, and ITRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A($0.03) per shareN/AITRMIterum TherapeuticsN/AN/AN/AN/A($0.12) per shareN/AKRONKronos Bio$9.19M4.46N/AN/A$2.73 per share0.25NHWKNightHawk Biosciences$6.38M0.00N/AN/A$2.82 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$10.01MN/A0.00∞N/AN/AN/AN/A8/18/2025 (Estimated)ITRMIterum Therapeutics-$24.77M-$0.99N/A∞N/AN/AN/A-90.85%8/13/2025 (Estimated)KRONKronos Bio-$112.67M-$1.07N/AN/AN/A-867.66%-64.55%-48.18%8/14/2025 (Estimated)NHWKNightHawk Biosciences-$43.44M-$1.99N/AN/AN/A-2,333.27%-91.62%-56.48%N/ALatest NHWK, AKTX, KRON, and ITRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ITRMIterum Therapeutics-$0.14-$0.14N/A-$0.14N/AN/A3/18/2025Q4 2024KRONKronos Bio-$0.30-$0.43-$0.13-$0.43$1.00 million$2.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/AKRONKronos BioN/AN/AN/AN/AN/ANHWKNightHawk BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.290.29ITRMIterum TherapeuticsN/A1.411.41KRONKronos BioN/A8.328.32NHWKNightHawk Biosciences0.270.990.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%ITRMIterum Therapeutics9.21%KRONKronos Bio64.09%NHWKNightHawk Biosciences21.16%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics38.90%ITRMIterum Therapeutics9.20%KRONKronos Bio24.40%NHWKNightHawk Biosciences15.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics932.18 million16.25 millionNot OptionableITRMIterum Therapeutics1040.00 million31.40 millionNot OptionableKRONKronos Bio10060.97 million45.62 millionOptionableNHWKNightHawk Biosciences7726.08 million21.94 millionOptionableNHWK, AKTX, KRON, and ITRM HeadlinesRecent News About These CompaniesIs NightHawk Biosciences Inc (NHWK) Stock a Good Investment?September 20, 2024 | aaii.comSCPXD Scorpius Holdings, Inc.July 21, 2024 | seekingalpha.comScorpius Holdings GAAP EPS of -$1.74April 29, 2024 | seekingalpha.comScorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major UniversityMarch 19, 2024 | globenewswire.comScorpius Holdings Accepted as a Member of the US Government's BioMaP-ConsortiumMarch 14, 2024 | globenewswire.comScorpius Holdings, Inc. Announces Closing of Public OfferingMarch 12, 2024 | globenewswire.comScorpius Holdings, Inc. Announces Pricing of Public OfferingMarch 8, 2024 | globenewswire.comScorpius Holdings, Inc. Announces Proposed Public Offering of Common StockMarch 7, 2024 | globenewswire.comScorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023March 7, 2024 | globenewswire.comScorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023March 7, 2024 | globenewswire.comScorpius Holdings, Inc. (SCPX)February 13, 2024 | uk.finance.yahoo.comNightHawk Biosciences Debuts SCPX Ticker on NYSE AmericanFebruary 7, 2024 | msn.comNightHawk Biosciences Unveils New Name and TickerFebruary 7, 2024 | msn.comNightHawk Biosciences Strikes Key Licensing and Financing DealsJanuary 31, 2024 | msn.comNightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing NoteJanuary 30, 2024 | finance.yahoo.comNightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a ...January 25, 2024 | bakersfield.comNightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical ProgramJanuary 25, 2024 | finance.yahoo.comNightHawk Biosciences: NightHawk's Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New ClientJanuary 17, 2024 | finanznachrichten.deNightHawk’s Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New ClientJanuary 16, 2024 | finance.yahoo.comNHWK: Transformational ChangesJanuary 11, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNHWK, AKTX, KRON, and ITRM Company DescriptionsAkari Therapeutics NASDAQ:AKTX$1.25 -0.05 (-3.85%) As of 10:02 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Iterum Therapeutics NASDAQ:ITRM$1.00 +0.03 (+2.55%) As of 10:04 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Kronos Bio NASDAQ:KRON$0.67 +0.00 (+0.22%) As of 10:04 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.NightHawk Biosciences NYSE:NHWKNightHawk Biosciences, Inc., an integrated biopharmaceutical company, develops, manufactures, and commercializes medical countermeasures that combat unmet and emerging biothreats. The company develops ANTHIM (obiltoxaximab), a monoclonal antibody antitoxin for the treatment of inhalational anthrax. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
